Literature DB >> 32675579

What one pandemic can teach us in facing another.

Wafaa M El-Sadr1.   

Abstract

Entities:  

Mesh:

Year:  2020        PMID: 32675579      PMCID: PMC7493777          DOI: 10.1097/QAD.0000000000002636

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.632


× No keyword cloud information.
Almost exactly 39 years ago, the US Centers for Disease Control reported five cases of Pneumocystis carinii pneumonia among previously healthy gay men [1]. By the end of 1985, HIV was reported from every region in the world. Three decades later, 75 million people have acquired HIV and about 32 million have died from it [2]. HIV was the first pandemic that shaped my career – as it has for so many of my peers. Indeed, it fundamentally changed how we think about and respond to major health threats. HIV continues to be a clarion call – for countless scientists, health providers and community advocates around the world. And, sadly, four decades on, this pandemic still rages across the globe. Today, for the first time in history, the world is experiencing two pandemics at the same time. What are the similarities and differences between the two pandemics? Are there lessons learned from confronting HIV that should guide the response to COVID-19 pandemic? In terms of similarities, both pandemics are caused by zoonotic viruses. For HIV, research confirmed that the virus was transmitted from nonhuman primates to humans while SARS-CoV-2 is thought to have originated in bats [3,4]. In addition, both viruses are transmitted from person to person. The predominance of HIV transmission through sexual route and via injection drug use has resulted in profound stigma associated with it [5-7]. At the same time, COVID-19-related stigma has already been noted, including blaming outsiders [8]. Another similarity is that both epidemics have shed light on gaps in health systems. HIV, as a chronic communicable disease, required a transformation from a focus on acute care to be able to deliver on the chronic and ongoing needs of people living with HIV [9,10]. The COVID-19 pandemic, in contrast, has highlighted the fragility of surveillance and contact tracing systems, the paucity of measures to protect health providers, and the limited infrastructure for advanced care [11-14]. The good news is that the decades of struggles in confronting the HIV epidemic provide important lessons relevant to the control of the COVID-19 pandemic. Firstly, political leadership is critically important. The early denial of the HIV epidemic in South Africa and the United States resulted in unnecessary loss of life [15-17]. Early denial of the risk of COVID-19 by leadership in the United States resulted in it leading the world in the number of cases and deaths. Similar reluctance in Brazil has resulted in the country leading all Latin American countries in the number of COVID-19 cases with an alarming number of deaths [18,19]. Secondly, perhaps the most durable legacy of the HIV response is the recognition of the critical importance of engaging communities, whether through the early voices of gay advocates in the United States or the vibrant participation of people living with HIV as peer educators around the world [20,21]. It has rapidly become evident that COVID-19 is disproportionately affecting African Americans and Latinos in the United States, with data showing them to be twice as likely to die from COVID-19. Similar adverse impacts have been noted among vulnerable populations in country after country around the world. We need to take the lessons learned from HIV and work to engage the communities most severely impacted by COVID-19. Thirdly, it is widely acknowledged that the successful global response to the HIV epidemic was because of strengthening all pillars of the health system [22]. Addressing the need for lifelong treatment for HIV required investment in laboratory and medication procurement systems, training and mentorship of diverse health cadres and development of innovative models of care. A similar comprehensive approach is needed in order to ensure an effective response to COVID-19. Fourthly, while during the early desperate years of the HIV epidemic, advocates reached for unproven treatment, they quickly became strong supporters of science-based interventions [23-25]. The harm caused by unproven HIV treatments should inspire caution and motivate a commitment to rigorous science in evaluating potential treatments and preventive measures for COVID-19. Fifthly, the HIV epidemic showed us the importance of using data to inform action. National surveys in African countries provide this kind of granular data [26]. COVID-19 data from New York City, as another example, point to specific zip codes with the highest burden of COVID-19 [27]. These are the areas where we must focus our efforts in order to achieve equity, where intensive outreach is needed, and where testing sites and treatment resources should be situated to allow for rapid identification of cases. Lastly, epidemics thrive on mistrust and myths. Conspiracy theories about HIV has jeopardized lives by provoking reluctance to get tested or to initiate treatment. As we face the COVID-19 epidemic, it behoves us to take the lessons from HIV to heart and identify trusted spokespersons armed with accurate information who can reach the affected populations with reliable information. Experiencing two concomitant pandemics is unprecedented. Although attention has shifted to COVID-19, I fear we risk forgetting that the HIV pandemic still affects millions of people. We risk turning our attention to the issue of the moment, neglecting other health threats that people face. With a generation of experience as our guide, I am hopeful that the lessons learned from the first pandemic that defined my career can help bring the second one under control and with far fewer lives lost.

Acknowledgements

The author gratefully acknowledge inputs from Jessica Justman and Joey Platt.

Conflicts of interest

There are no conflicts of interest.
  16 in total

Review 1.  The impact of HIV scale-up on health systems: A priority research agenda.

Authors:  Miriam Rabkin; Wafaa M El-Sadr; Kevin M De Cock
Journal:  J Acquir Immune Defic Syndr       Date:  2009-11       Impact factor: 3.731

2.  Why reinvent the wheel? Leveraging the lessons of HIV scale-up to confront non-communicable diseases.

Authors:  Miriam Rabkin; Wafaa M El-Sadr
Journal:  Glob Public Health       Date:  2011

3.  Strategies used by people who inject drugs to avoid stigma in healthcare settings.

Authors:  Dea L Biancarelli; Katie B Biello; Ellen Childs; M Drainoni; Peter Salhaney; Alberto Edeza; Matthew J Mimiaga; Richard Saitz; Angela R Bazzi
Journal:  Drug Alcohol Depend       Date:  2019-03-08       Impact factor: 4.492

4.  Critical Care Utilization for the COVID-19 Outbreak in Lombardy, Italy: Early Experience and Forecast During an Emergency Response.

Authors:  Giacomo Grasselli; Antonio Pesenti; Maurizio Cecconi
Journal:  JAMA       Date:  2020-04-28       Impact factor: 56.272

5.  Pneumocystis pneumonia--Los Angeles.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  1981-06-05       Impact factor: 17.586

6.  Effects of treatment intensification with hydroxyurea in HIV-infected patients with virologic suppression.

Authors:  D V Havlir; P B Gilbert; K Bennett; A C Collier; M S Hirsch; P Tebas; E M Adams; L J Wheat; D Goodwin; S Schnittman; M K Holohan; D D Richman
Journal:  AIDS       Date:  2001-07-27       Impact factor: 4.177

Review 7.  The global response and unmet actions for HIV and sex workers.

Authors:  Kate Shannon; Anna-Louise Crago; Stefan D Baral; Linda-Gail Bekker; Deanna Kerrigan; Michele R Decker; Tonia Poteat; Andrea L Wirtz; Brian Weir; Marie-Claude Boily; Jenny Butler; Steffanie A Strathdee; Chris Beyrer
Journal:  Lancet       Date:  2018-07-20       Impact factor: 79.321

8.  Lack of response to suramin in patients with AIDS and AIDS-related complex.

Authors:  L D Kaplan; P R Wolfe; P A Volberding; P Feorino; J A Levy; D I Abrams; D Kiprov; R Wong; L Kaufman; M S Gottlieb
Journal:  Am J Med       Date:  1987-03-23       Impact factor: 4.965

9.  HIV cure research community engagement in North Carolina: a mixed-methods evaluation of a crowdsourcing contest.

Authors:  Allison Mathews; Samantha Farley; Meredith Blumberg; Kimberley Knight; Lisa Hightow-Weidman; Kate Muessig; Stuart Rennie; Joseph Tucker
Journal:  J Virus Erad       Date:  2017-10-01

Review 10.  Zoonotic origins of human coronaviruses.

Authors:  Zi-Wei Ye; Shuofeng Yuan; Kit-San Yuen; Sin-Yee Fung; Chi-Ping Chan; Dong-Yan Jin
Journal:  Int J Biol Sci       Date:  2020-03-15       Impact factor: 6.580

View more
  3 in total

Review 1.  HIV and COVID-19 in Latin America and the Caribbean.

Authors:  Patricia J Garcia; Diego M Cabrera; Paloma M Cárcamo; Monica M Diaz
Journal:  Curr HIV/AIDS Rep       Date:  2022-01-29       Impact factor: 5.495

2.  "What will we do if we get infected?": An interview-based study of the COVID-19 pandemic and its effects on the health and safety of sex workers in the United States.

Authors:  Denton Callander; Alicia Thilani Singham Goodwin; Dustin T Duncan; Christian Grov; Wafaa El-Sadr; Mariah Grant; R J Thompson; Molly Simmons; J Leigh Oshiro-Brantly; Krish J Bhatt; Étienne Meunier
Journal:  SSM Qual Res Health       Date:  2021-12-08

3.  Special section: COVID-19 among people living with HIV.

Authors:  Michael Saag
Journal:  AIDS       Date:  2020-10-01       Impact factor: 4.632

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.